Tardive dyskinesia and withdrawal emergent syndrome in children

Expert Review of Neurotherapeutics

Volumn 10, Issue 6, 2010, Pages 893-901

  Mejia, Nicte I ^a   Jankovic, Joseph ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antiemetic; Antipsychotic; Children; Dopamine; Metoclopramide; Neuroleptic; Pediatric; Tardive; Tardive dyskinesia; Tetrabenazine; Withdrawal emergent syndrome

Indexed keywords

DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

CHILDHOOD; DISEASE COURSE; HUMAN; IATROGENIC DISEASE; MOTOR DYSFUNCTION; OUTCOME ASSESSMENT; PHENOMENOLOGY; PREVALENCE; REVIEW; RISK ASSESSMENT; TARDIVE DYSKINESIA; WITHDRAWAL SYNDROME;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; DOPAMINE ANTAGONISTS; DYSKINESIA, DRUG-INDUCED; HUMANS; MENTAL DISORDERS; PREVALENCE;

EID: 77953187393     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.58     Document Type: Review

References (90)

1. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin. Neuropharmacol. 18(3), 197-214 (1995).
2. Rodnitzky RL. Drug-induced movement disorders in children and adolescents. Expert Opin. Drug Saf. 4(1), 91-102 (2005).
3. Fahn S. The tardive dyskinesias. In: Recent Advances in Clinical Neurology, Volume 4. Matthews WB, Glaser GH (Eds). Churchill Livingstone, Edinburgh, UK 229-260 (1984).
4. Klawans HL, Brandabur MM. Chorea in childhood. Pediatr. Ann. 22(1), 41-46, 49-50 (1993).
5. Wolf DW, Wagner KD. Tardive dyskinesia, tardive dystonia, and tardive Tourette's syndrome in children and adolescents. J. Child Adolesc. Psychopharmacol. 3(4), 175-198 (1993).
6. Stacy M, Cardoso F, Jankovic J. Tardive stereotopy and other movement disorders in tardive dyskinesia. Neurology 43(5), 937-941 (1993).
7. Polizos P, Engelhardt DM, Hoffman SP, Waizer J. Neurological consequences of psychotropic drug withdrawal in schizophrenic children. J. Autism Child. Schizophr. 3(3), 247-253 (1973).
8. Paulson GW, Rizvi CA, Crane GE. Tardive dyskinesia as a possible sequel of long-term therapy with phenothiazines. Clin. Pediatr. 14(10), 953-955 (1975).
9. Gualtieri CT, Schroeder SR, Hicks RE, Quade D. Tardive dyskinesia in young mentally retarded individuals. Arch. Gen. Psychiatry 43(4), 335-340 (1986).
10. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J. Am. Acad. Child. Adolesc. Psychiatry 36(6), 835-843 (1997).
11. Kumra S, Jacobsen LK, Lenane M et al. Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia. J. Am. Acad. Child. Adolesc. Psychiatry 37(2), 221-227 (1998).
12. Reyes M, Olah R, Csaba K, Augustyns I, Eerdekens M. Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. Eur. Child. Adolesc. Psychiatry 15(2), 97-104 (2006).
13. Wonodi I, Reeves G, Carmichael D et al. Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov. Disord. 22(12), 1777-1782 (2007).
14. McAndrew, Case Q, Treffert DA. Effects of prolonged phenothiazine intake on psychotic and other hospitalized children. J. Autism Child. Schizophr. 2(1), 75-91 (1972).
15. Browning DH, Ferry PC. Tardive dyskinesia in a ten-year-old boy: an undesirable sequel of phenothiazine medication. Clin. Pediat. 15(10), 955-957 (1976).
16. Caine ED, Margolin DI, Brown GL, Ebert MH. Gilles de la Tourette's syndrome, tardive dyskinesia, and psychosis in an adolescent. Am. J. Psychiatry 135(2), 241-242 (1978).
17. McLean P, Casey DE. Tardive dyskinesia in an adolescent. Am. J. Psychiatry 135(8), 969-971 (1978).
18. Mizrahi EM, Holtzman D, Tharp B. Haloperidol-induced tardive dyskinesia in a child with Gilles de la Tourette's disease. Arch. Neurol. 37(12), 780 (1980).
19. Caine ED, Polinsky RJ. Tardive dyskinesia in persons with Gilles de la Tourette's disease. Arch. Neurol. 38(7), 471-472 (1981).
20. Putnam PE, Orenstein SR, Wessel HB, Stowe RM. Tardive dyskinesia associated with use of metoclopramide in a child. J. Pediatr. 121(6), 983-985 (1992).
21. Kompoliti K, Goetz C. Hyperkinetic movement disorders misdiagnosed as tics in Gilles de la Tourette syndrome. Mov. Disord. 13(3), 477-480 (1998).
22. Ahmed S, Chengappa KN, Naidu VR, Baker RW, Parepally H, Schooler NR. Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J. Clin. Psychiatry 59(9), 472-477 (1998).
23. Mejia NI, Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov. Disord. 20(1), 86-89 (2005).
24. Gualtieri CT, Quade D, Hicks RE, Mayo JP, Schroeder SR. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Am. J. Psychiatry 141(1), 20-23 (1984).
25. Perry R, Campbell M, Green WH et al. Neuroleptic-related dyskinesias in autistic children: a prospective study. Psychopharmacol. Bull. 21(1), 140-143 (1985).
26. Campbell M, Adams P, Perry R, Spencer EK, Overall JE. Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol. Bull. 24(2), 251-255 (1988).
27. Malone RP, Ernst M, Godfrey KA, Locascio JJ, Campbell M. Repeated episodes of neuroleptic-related dyskinesias in autistic children. Psychopharmacol. Bull. 27(2), 113-117 (1991).
28. Shay J, Sanchez LE, Cueva JE, Armenteros J, Overall JE, Campbell M. Neuroleptic-related dyskinesias and stereotypies in autistic children: videotaped ratings. Psychopharmacol. Bull. 29(3), 359-363 (1993).
29. Armenteros JL, Adams PB, Campbell M, Eisenberg ZW. Haloperidol-related dyskinesias and pre- and perinatal complications in autistic children. Psychopharmacol. Bull. 31(2), 363-369 (1995).
30. MacEwan T, Morton MJS. Use of clozapine in a child with treatment-resistant schizophrenia. Br. J. Psychiatry 168(3), 376-378 (1996).
31. Hill RM, Desmond MM, Kay JL. Extrapyramidal dysfunction in an infant of a schizophrenic mother. J. Pediatr. 69(4), 589-595 (1966).
32. Tamer A, McKey R, Arias D, Worley L, Fogel BJ. Phenothiazine-induced extrapyramidal dysfunction in the neonate. J. Pediatr. 75(3), 479-480 (1969).
33. Holmes C, Flaherty R. Trimethobenzamide Hcl (Tigan)-induced extrapyramidal dysfunction in a neonate. J. Pediatr. 89(4), 669-670 (1976).
34. Gualtieri CT, Barnhill J, McGimsey J, Schell D. Tardive dyskinesia and other movement disorders in children treated with psychotropic drugs. J. Am. Acad. Child Psychiatry 19(3), 491-510 (1980).
35. Sexson WR, Barak Y. Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy. J. Perinatol. 9(2), 170-172 (1989).
36. Rosebush PI, Kennedy K, Dalton BM Mazurek MF. Protracted akathisia after risperidone withdrawal. Am. J. Psychiatry 154(3), 437-438 (1997).
37. Giladi N, Shabtai H. Melatonin-induced withdrawal emergent dyskinesia and akathisia. Mov. Disord. 14(2), 381-382 (1999).
38. Lore C. Risperidone and withdrawal dyskinesia. J. Am. Acad. Child. Adolesc. Psychiatry 39(8), 941 (2000).
39. Connor DF, Fletcher KE, Wood JS. Neuroleptic-related dyskinesias in children and adolescents. J. Clin. Psychiatry 62(12), 967-974 (2001).
40. McCracken JT, McGough J, Shah B et al. Risperidone in children with autism and serious behavioral problems. N. Engl. J. Med. 347(5), 314-321 (2002).
41. Brasic JR, Barnett JY, Kowalik S, Tsaltas MO, Ahmad R. Neurobehavioral assessment of children and adolescents attending a developmental disabilities clinic. Psychol. Rep. 95(3 Pt 2), 1079-1086 (2004).
42. Haas M, Karcher K, Pandina GJ. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents. J. Child Adolesc. Psychopharmacol. 18(4), 337-345 (2008).
43. Fido A, Al-Saad S. Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait. Med. Princ. Pract. 17, 415-418 (2008).
44. Silverstein FS, Johnston MV. Risks of neuroleptic drugs in children. J. Child Neurol. 2(1), 41-43 (1987).
45. Bruun RD. Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder. Am. J. Psychiatry 145(5), 621-624 (1988).
46. Kasantikul D, Kanchanatawan B. Antipsychotic-induced tardive movement disorders: a series of twelve cases. J. Med. Assoc. Thai. 90(1), 188-194 (2007).
47. Woerner MG, Kane JM, Lieberman JA et al. The prevalence of tardive dyskinesia. J. Clin. Psychopharmacol. 11(1), 34-42 (1991).
48. Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch. Intern. Med. 153(12), 1469-1475 (1993).
49. Jankovic J. Stereotypies in autistic and other childhood disorders. In: Paediatric Movement Disorders. Fernandez Alvarez E, Arzimanoglou A, Tolosa E (Eds). John Libbey Eurotex Limited, Montrouge, France 247-260 (2005).
50. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J. Clin. Psychopharmacol. 8 (S4), S52-S56 (1988).
51. Cardoso F, Vargas AP, Oliveira LD, Guerra AA, Amaral SV. Persistent Sydenham's chorea. Mov. Disord. 14(5), 805-807 (1999).
52. Goldman S, Wang C, Salgado MW, Greene PE, Kim M, Rapin I. Motor sterotypies in children with autism and other developmental disorders. Dev. Med. Child Neurol. 51(1), 30-38 (2009).
53. Harris KM, Mahone EM, Singer HS. Nonautistic motor stereotypies: clinical features and longitudinal follow-up. Pediatr. Neurol. 38(4), 267-272 (2008).
54. Freeman RD, Soltanifar A, Baer S. Stereotypic movement disorder: easily missed. Dev. Med. Child Neurol. DOI: 10.111/j.1469-8749.2010.03627.x (2010) (Epub ahead of print).
55. Mahone EM, Bridges D, Prahme C, Singer HS. Repetitive arm and hand movements (complex motor stereotypies) in children. J. Pediatr. 145(3), 391-395 (2004).
56. Peña MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Ann. Neurol. (2010) (In press).
57. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement - a review of the clinical benefits and medicolegal risks of metoclopramide. Nat. Clin. Pract. Gastroenterol. Hepatol. 3, 138-148 (2006).
58. Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J. Clin. Pharmacol. 48(3), 379-384 (2008).
59. Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Arch. Int. Med. 149(11), 2386-2392 (1989).
60. Dean CE, Thuras PD. Mortality and tardive dyskinesia: long-term study using the US National Death Index. Br. J. Psychiatry 194(4), 360-364 (2009).
61. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J. Clin. Psychiatry 65(S9), S16-S20 (2004).
62. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol. Psychiatr. 3(2), 123-134 (1998).
63. Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J. Child Adolesc. Psychopharmacol. 17(5), 647-656 (2007).
64. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr. Opin. Psychiatry 21(2), 151-156 (2008).
65. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry 161(3), 414-425 (2004).
66. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48(2), 358-362 (1997).
67. Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol. 8(9), 844-856 (2009).
68. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am. J. Psychiatry 156(8), 1279-1281 (1999).
69. Vuong K, Hunter CB, Mejia N, Jankovic J. Safety and efficacy of tetrabenazine in childhood hyperkinetic movement disorders. Mov. Disord. 19(S9), 422 (2004).
70. Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev. Neurother. 6(1), 7-17 (2006).
71. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov. Disord. 22(2), 193-197 (2007). (Pubitemid 46374760)
72. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment. Pharmacol. Ther. 31(1), 11-19 (2010).
73. Franzini A, Marras C, Ferroli P et al. Long-term high-frequency bilateral pallidal stimulation for neuroleptic-induced tardive dystonia. A report of two cases. J. Neurosurg. 102(4), 71-725 (2005).
74. Kefalopoulou Z, Paschali A, Markaki E, Vassilakos P, Ellul J, Constantoyannis C. A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation. Acta Neurol. Scand. 119(4), 269-273 (2009).
75. Aberg K, Adkins DE, Bukszar J et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol. Psychiatry 67(3), 279-282 (2010).
76. Tsai HT, Caroff SN, Miller DD et al. A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B(1), 336-340 (2010).
77. Novak G, Gallo A, Zai CC et al. Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia. Psychiatr. Genet. 20(1), 39-43 (2010).
78. Wilffert B, Al Hadithy AF, Sing VJ et al. The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX. J. Psychopharmacol. 23(6), 652-659 (2009).
79. Al Hadithy AF, Ivanova SA, Pechlivanoglou P et al. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(3), 475-481 (2009).
80. Al-Janabi I, Arranz MJ, Blakemore Al et al. Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatr. Genet. 19(6), 305-311 (2009).
81. Zhang XY, Xiu MH, Chen DC et al. Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. J. Psychiatr. Res. 144(7), 429-433 (2009).
82. Zai CC, Tiwari AK, Basile V et al. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. Pharmacogenomics J. 9(3), 168-174 (2009).
83. Zai CC, Tiwari AK, Basile V et al. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and superoxide dismutase 2 (SOD2, MnSOD) genes. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(1), 50-56 (2010).
84. Zai CC, Tiwari AK, De Luca V et al. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur. Neuropsychopharmacol. 19(5), 317-328 (2009).
85. De Luca V, Souza RP, Viggiano E et al. MDR1 gene in tardive dyskinesia scale scores: comparison of strategies for quantitative trait haplotype analysis. Schizophr. Res. 110(1-3), 200-201 (2009).
86. Liou YJ, Chen ML, Wang YC et al. Analysis of genetic variations in the human Par-4 (PAWR) gene and tardive dyskinesia in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B(2), 439-440 (2009).
87. Park SW, Lee JG, Kong BG et al. Genetic association of BDNF val66met and GSK-3b-50T/C polymorphisms with tardive dyskinesia. Psychiatry Clin. Neurosci. 63(4), 433-439 (2009).
88. Kang SG, Lee HJ, Choi JE, An H, Rhee M, Kim L. Association study between gluthathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia. Hum. Psychoharmacol. 24(1), 55-60 (2009).
89. Tsai HT, North KE, West SL, Poole C. The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a meta-analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B(1), 57-66 (2010).
90. Rizos EN, Chatziioannou S, Douzenis A et al. Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a DAT scan. Eur. Neuropsychopharmacol. 20(2), 132-136 (2010).